Usefulness of HIF-1 Imaging for Determining Optimal Timing of Combining Bevacizumab and Radiotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 75, Issue 2, 2009, Pages 463-467

  Ou, Guangfei ^a,b   Itasaka, Satoshi ^b   Zeng, Lihua ^b   Shibuya, Keiko ^b   Yi, Junlin ^a   Harada, Hiroshi ^b,c   Hiraoka, Masahiro ^b  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Antiangiogenesis; bevacizumab; HIF 1; hypoxia imaging; hypoxia inducible factor 1; radiation

Indexed keywords

ANTIANGIOGENESIS; BEVACIZUMAB; HIF-1; HYPOXIA IMAGING; HYPOXIA-INDUCIBLE FACTOR-1;

OPTIMIZATION; RADIOTHERAPY; TIME MEASUREMENT; TUMORS; WINDOWS;

RADIATION EFFECTS;

BEVACIZUMAB; HYPOXIA INDUCIBLE FACTOR 1ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; IMAGING; IN VIVO STUDY; LUNG ADENOCARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION; RADIATION DOSE; REPORTER GENE; UPREGULATION; XENOGRAFT;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; CELL HYPOXIA; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; GENES, REPORTER; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; IN SITU NICK-END LABELING; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; RANDOM ALLOCATION; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 69549122382     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.02.083     Document Type: Article

References (17)

1. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 285 (1971) 1182-1186
2. Boehm T., Folkman J., Browder T., et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390 (1997) 404-407
3. Nieder C., Wiedenmann N., Andratschke N., et al. Current status of angiogenesis inhibitors combined with radiation therapy. Cancer Treatment Rev 32 (2006) 348-364
4. Senan S., and Smit E.F. Design of clinical trials of radiation combined with antiangiogenic therapy. Oncologist 12 (2007) 465-477
5. Jain R.K. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
6. Murata R., Nishimura Y., Hiraoka M., et al. An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of mammary carcinoma. Int J Radiat Oncol Biol Phys 37 (1997) 1107-1113
7. Williams K.J., Telfer B.A., Brave S., et al. ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: Schedule-dependent enhancement of antitumor activity. Clin Cancer Res 10 (2004) 8587-8593
8. Winkler F., Kozin S.V., Tong R.T., et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6 (2004) 553-563
9. Dings R.P.M., Loren M., Heun H., et al. Scheduling of radiation with angiogenesis inhibitors Anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res 13 (2007) 3395-3402
10. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3 (2003) 721-732
11. Hirota K., and Semenza G.L. Regulation of hypoxia-inducible factor 1 by prolyl and asparaginyl hydroxylases. Biochem Biophys Res Commun 338 (2005) 610-616
12. Harada H., Kizaka-Kondoh S., and Hiraoka M. Optical imaging of tumor hypoxia and evaluation of efficacy of a hypoxia-targeting drug in living animals. Mol Imaging 4 (2005) 182-193
13. Ferrara N., Hillan K.J., Gerber H.P., et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3 (2004) 391-400
14. Zeng L., Kizaka-Kondoh S., Itasaka S., et al. Hypoxia inducible factor-1 influences sensitivity to paclitaxel of human lung cancer cell lines under normoxic conditions. Cancer Sci 98 (2007) 1394-1401
15. Zeng L., Ou G., Itasaka S., et al. TS-1 enhances the effect of radiotherapy by suppressing radiation-induced hypoxia-inducible factor-1 activation and inducing endothelial cell apoptosis. Cancer Sci 99 (2008) 2327-2335
16. Dewhirst M.W., Cao Y., and Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 8 (2008) 425-437
17. Harada H., Itasaka S., Kizaka-Kondoh S., et al. Akt/mTOR pathway assures the synthesis of HIF-1alpha protein in a glucose- and reoxygenation-dependent manner in irradiated tumors. J Biol Chem 284 (2009) 5332-5342